{"content":"<li class=\"n-box-item date-title\" data-end=\"1576299599\" data-start=\"1576213200\" data-txt=\"Monday, December 23, 2019\">Friday, December 13, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3526306\" data-ts=\"1576278551\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526306-vxx-amza-tvix-and-vixy-among-weekly-etf-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VXX, AMZA, TVIX and VIXY among weekly ETF movers</a></h4><ul><li><strong>Gainers: </strong>Direxion Daily MSCI Mexico Bull 3X Shares (NYSEARCA:<a href='https://seekingalpha.com/symbol/MEXX' title='Direxion Daily MSCI Mexico Bull 3X ETF'>MEXX</a>) <font color=\"green\">+20.0%</font>.</li><li>Direxion South Korea Bull 3X (NYSEARCA:<a href='https://seekingalpha.com/symbol/KORU' title='Direxion Daily South Korea Bull 3x Shares ETF'>KORU</a>) <font color=\"green\">+15.9%</font>.</li><li>Russia Bull 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/RUSL' title='Direxion Daily Russia Bull 3x Shares ETF'>RUSL</a>) <font color=\"green\">+13.8%</font>.</li><li>Semiconductor Bull 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>) <font color=\"green\">+12.6%</font>.</li><li>Natural Gas Bull 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/GASL' title='Direxion Daily Natural Gas Related Bull 3x Shares ETF'>GASL</a>) <font color=\"green\">+12.2%</font>.</li><li><strong>Losers: </strong>VS 2X VIX Short Term (NASDAQ:<a href='https://seekingalpha.com/symbol/TVIX' title='VelocityShares Daily 2x VIX Short-Term ETN'>TVIX</a>) <font color=\"red\">-14.0%</font>.</li><li>Direxion Natural Gas Bear 3X (NYSEARCA:<a href='https://seekingalpha.com/symbol/GASX' title='Direxion Daily Natural Gas Related Bear 3X Shares ETF'>GASX</a>) <font color=\"red\">-13.7%</font>.</li><li>Russia Bear 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/RUSS' title='Direxion Daily Russia Bear 3x Shares ETF'>RUSS</a>) <font color=\"red\">-12.7%</font>.</li><li>Semiconductor Bear 3X Direxion (NYSEARCA:<a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>) <font color=\"red\">-12.2%</font>.</li><li>Ultra VIX Short-Term Fut Proshares (NYSEARCA:<a href='https://seekingalpha.com/symbol/UVXY' title='ProShares Ultra VIX Short-Term Futures ETF'>UVXY</a>) <font color=\"red\">-10.9%</font>.</li><li><strong>Top non-leveraged gainers: </strong>Bioshares Biotech Clinical Trial (NYSEARCA:<a href='https://seekingalpha.com/symbol/BBC' title='ETFis Series Trust I - Virtus LifeSci Biotech Clinical Trials ETF'>BBC</a>) <font color=\"green\">+8.9%</font>.</li><li>G-X Copper Miners ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/COPX' title='Global X Copper Miners ETF'>COPX</a>) <font color=\"green\">+7.2%</font>.</li><li>Mexico Ishares MSCI ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWW' title='iShares MSCI Mexico Capped ETF'>EWW</a>)<font color=\"green\"> +6.4%</font>.</li><li>Infracap MLP ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/AMZA' title='InfraCap MLP ETF'>AMZA</a>) <font color=\"green\">+5.7%</font>.</li><li>Global X Cannabis ETF (NASDAQ:<a href='https://seekingalpha.com/symbol/POTX' title='Global X Funds - Global X Cannabis Etf'>POTX</a>)<font color=\"green\"> +5.6%</font>.</li><li><strong>Top non-leveraged losers: </strong>VIX Short-Term Futures Proshares (NYSEARCA:<a href='https://seekingalpha.com/symbol/VIXY' title='ProShares VIX Short-Term Futures ETF'>VIXY</a>) <font color=\"red\">-7.2%</font>.</li><li>iPath.B S&amp;P 500 VIX Short-Term Futures ETN (BATS:<a href='https://seekingalpha.com/symbol/VXX' title='iPath S&P 500 VIX Short-Term Futures ETN'>VXX</a>)<font color=\"red\"> -7.2%</font>.</li><li>VS VIX Short Term (NASDAQ:<a href='https://seekingalpha.com/symbol/VIIX' title='VelocityShares VIX Short-Term ETN'>VIIX</a>)<font color=\"red\"> -7.0%</font>.</li><li>Schwab US REIT ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/SCHH' title='Schwab Strategic Trust - Schwab U.S. REIT ETF'>SCHH</a>) <font color=\"red\">-4.6%</font>.</li><li>S&amp;P REIT Index (NYSEARCA:<a href='https://seekingalpha.com/symbol/FRI' title='First Trust Exchange-Traded Fund - First Trust S&P REIT Index Fund'>FRI</a>) <font color=\"red\">-4.2%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526306\" data-linked=\"VXX, AMZA, TVIX and VIXY among weekly ETF movers\" data-tweet=\"$MEXX $KORU $RUSL - VXX, AMZA, TVIX and VIXY among weekly ETF movers https://seekingalpha.com/news/3526306-vxx-amza-tvix-and-vixy-among-weekly-etf-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526306-vxx-amza-tvix-and-vixy-among-weekly-etf-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526304\" data-ts=\"1576277559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526304-swn-rgnx-and-cytk-among-notable-after-hours-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SWN, RGNX and CYTK among notable after hours movers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GVA' title='Granite Construction Incorporated'>GVA</a> <font color=\"green\">+4.8%</font>. <a href='https://seekingalpha.com/symbol/CYTK' title='Cytokinetics, Incorporated'>CYTK</a> <font color=\"green\">+3.3%</font>. <a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a> <font color=\"green\">+3.1%</font>. <a href='https://seekingalpha.com/symbol/BRFS' title='BRF S.A.'>BRFS</a> <font color=\"green\">+2.1%</font>. <a href='https://seekingalpha.com/symbol/SWN' title='Southwestern Energy Company'>SWN</a> <font color=\"green\">+2%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/AUDC' title='AudioCodes Ltd.'>AUDC</a> <font color=\"red\">-3.8%</font>.  <a href='https://seekingalpha.com/symbol/CX' title='CEMEX, S.A.B. de C.V.'>CX</a> <font color=\"red\">-2.6%</font>. <a href='https://seekingalpha.com/symbol/NK' title='NantKwest, Inc.'>NK</a> <font color=\"red\">-1.4%</font>. <a href='https://seekingalpha.com/symbol/RGNX' title='REGENXBIO Inc.'>RGNX</a> <font color=\"red\">-1%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526304\" data-linked=\"SWN, RGNX and CYTK among notable after hours movers\" data-tweet=\"$GVA $CYTK $TEN - SWN, RGNX and CYTK among notable after hours movers https://seekingalpha.com/news/3526304-swn-rgnx-and-cytk-among-notable-after-hours-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526304-swn-rgnx-and-cytk-among-notable-after-hours-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526284\" data-ts=\"1576272797\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526284-fda-oks-cv-benefit-claim-for-amarins-vascepa\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs CV benefit claim for Amarin&#39;s Vascepa</a></h4><ul><li>As expected, the FDA <a href=\"https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups\" target=\"_blank\">approves </a>a cardiovascular &#40;CV&#41; benefit claim for Amarin's (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a>) Vascepa (icosapent ethyl) based on results from the large-scale REDUCE-IT study.</li><li>The approved use is as an adjunct therapy to reduce the risk of CV events in adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. Patients must also have either established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease.</li><li>Trading has yet to resume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526284\" data-linked=\"FDA OKs CV benefit claim for Amarin&#39;s Vascepa\" data-tweet=\"$AMRN - FDA OKs CV benefit claim for Amarin&#39;s Vascepa https://seekingalpha.com/news/3526284-fda-oks-cv-benefit-claim-for-amarins-vascepa?source=tweet\" data-url=\"https://seekingalpha.com/news/3526284-fda-oks-cv-benefit-claim-for-amarins-vascepa\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>234&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526261\" data-ts=\"1576268611\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HZNP\" target=\"_blank\">HZNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526261-fda-advisory-committee-backs-horizons-teprotumumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA advisory committee backs Horizon&#39;s teprotumumab</a></h4><ul><li>The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted 12-0 that the benefits of Horizon Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Therapeutics Public Limited Company'>HZNP</a>) teprotumumab outweigh the risks for the treatment of thyroid eye disease &#40;TED&#41;.</li><li>The FDA's action date is March 8, 2020.</li><li>Teprotumumab is a fully human monoclonal antibody that binds to (inhibits) a protein called insulin-like growth factor 1 receptor (IGF-1R). TED is a rare autoimmune disorder in which IGF-1R is overexpressed in the eye.</li><li><strong>Update</strong>: Shares will resume trading at 4:30 pm ET.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526261\" data-linked=\"FDA advisory committee backs Horizon&#39;s teprotumumab\" data-tweet=\"$HZNP - FDA advisory committee backs Horizon&#39;s teprotumumab https://seekingalpha.com/news/3526261-fda-advisory-committee-backs-horizons-teprotumumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3526261-fda-advisory-committee-backs-horizons-teprotumumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526258\" data-ts=\"1576267643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EGRX\" target=\"_blank\">EGRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eagle Pharma on go to launch Alimta alternative in early 2022</a></h4><ul><li>Eagle Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EGRX' title='Eagle Pharmaceuticals, Inc.'>EGRX</a> <font color=\"green\">+2.5%</font>) has <a href=\"https://seekingalpha.com/pr/17728049-eagle-pharmaceuticals-reaches-settlement-agreement-eli-lilly-for-pemfexy-pemetrexed-for\" target=\"_blank\">settled </a>all patent issues with Eli Lilly (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color=\"red\">-0.3%</font>) related to the latter's chemo drug Alimta (pemetrexed for injection).</li><li>Under the terms of the settlement agreement, Eagle will be allowed to initially enter the U.S. market with its alternative offering, Pemfexy, on February 1, 2022 followed by full commercial launch on April 1, 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526258\" data-linked=\"Eagle Pharma on go to launch Alimta alternative in early 2022\" data-tweet=\"$EGRX $LLY - Eagle Pharma on go to launch Alimta alternative in early 2022 https://seekingalpha.com/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022?source=tweet\" data-url=\"https://seekingalpha.com/news/3526258-eagle-pharma-on-go-to-launch-alimta-alternative-in-early-2022\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526256\" data-ts=\"1576266830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526256-secureworks-leads-technology-gainers-phreesia-and-nextgen-healthcare-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SecureWorks leads technology gainers; Phreesia and NextGen Healthcare among losers</a></h4><ul><li><b>Gainers:</b> SecureWorks (NASDAQ:<a href='https://seekingalpha.com/symbol/SCWX' title='SecureWorks Corp.'>SCWX</a>) <font color=\"green\">+9%</font>. Arlo Technologies (NYSE:<a href='https://seekingalpha.com/symbol/ARLO' title='Arlo Technologies, Inc.'>ARLO</a>) <font color=\"green\">+8%</font>. Rapid7 (NASDAQ:<a href='https://seekingalpha.com/symbol/RPD' title='Rapid7, Inc.'>RPD</a>) <font color=\"green\">+8%</font>. Wrap Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/WRTC' title='Wrap Technologies, Inc.'>WRTC</a>) <font color=\"green\">+8%</font>. EchoStar (NASDAQ:<a href='https://seekingalpha.com/symbol/SATS' title='EchoStar Corporation'>SATS</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers:</b> Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-34%</font>. NextGen Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/NXGN' title='NextGen Healthcare, Inc.'>NXGN</a>) <font color=\"red\">-13%</font>. Applied DNA Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/APDN' title='Applied DNA Sciences, Inc.'>APDN</a>) <font color=\"red\">-9%</font>. Phreesia (NYSE:<a href='https://seekingalpha.com/symbol/PHR' title='Phreesia, Inc.'>PHR</a>) <font color=\"red\">-8%</font>. Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Corporation'>INAP</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526256\" data-linked=\"SecureWorks leads technology gainers; Phreesia and NextGen Healthcare among losers\" data-tweet=\"$SCWX $ARLO $RPD - SecureWorks leads technology gainers; Phreesia and NextGen Healthcare among losers https://seekingalpha.com/news/3526256-secureworks-leads-technology-gainers-phreesia-and-nextgen-healthcare-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526256-secureworks-leads-technology-gainers-phreesia-and-nextgen-healthcare-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526250\" data-ts=\"1576263647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526250-energy-materials-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Lonestar Resources US (NASDAQ:<a href='https://seekingalpha.com/symbol/LONE' title='Lonestar Resources US Inc.'>LONE</a>) <font color=\"green\">+9%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+8%</font>. Flexible Solutions International (NYSEMKT:<a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International Inc.'>FSI</a>) <font color=\"green\">+8%</font>. Coeur Mining (NYSE:<a href='https://seekingalpha.com/symbol/CDE' title='Coeur Mining, Inc.'>CDE</a>) <font color=\"green\">+6%</font>. Platinum Group Metals (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLG' title='Platinum Group Metals Ltd.'>PLG</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>TuanChe (NASDAQ:<a href='https://seekingalpha.com/symbol/TC' title='TuanChe Limited'>TC</a>) <font color=\"red\">-9%</font>. Oasis Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/OAS' title='Oasis Petroleum Inc.'>OAS</a>) <font color=\"red\">-8%</font>. Antero Resources (NYSE:<a href='https://seekingalpha.com/symbol/AR' title='Antero Resources Corporation'>AR</a>) <font color=\"red\">-7%</font>. Whiting Petroleum (NYSE:<a href='https://seekingalpha.com/symbol/WLL' title='Whiting Petroleum Corporation'>WLL</a>) <font color=\"red\">-7%</font>. Range Resources (NYSE:<a href='https://seekingalpha.com/symbol/RRC' title='Range Resources Corporation'>RRC</a>) <font color=\"red\">-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526250\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers\" data-tweet=\"$LONE $CEI $FSI - Energy/Materials - Top 5 Gainers / Losers https://seekingalpha.com/news/3526250-energy-materials-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526250-energy-materials-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526245\" data-ts=\"1576262668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSX\" target=\"_blank\">BSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526245-fda-clears-boston-scientific-single-use-duodenoscope\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears Boston Scientific single-use duodenoscope</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17728015-boston-scientific-receives-fda-clearance-for-worlds-first-single-use-duodenoscope-exalt-model\" target=\"_blank\">grants 510(k) clearance</a> to Boston Scientific's (<a href='https://seekingalpha.com/symbol/BSX' title='Boston Scientific Corporation'>BSX</a> <font color=\"green\">+0.7%</font>) EXALT Model D, a single-use duodenoscope (a hollow lighted tube for inspecting the small intestine) for use in endoscopic retrograde cholangiopancreatography procedures (aimed at diagnosing issues in the liver, gallbladder, bile ducts and pancreas).</li><li>The company says it is the first such single-use device available in the U.S. (other duodenoscopes are reusable which carries an infection risk if not cleaned thoroughly).</li><li>Limited commercial launch will commence next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526245\" data-linked=\"FDA clears Boston Scientific single-use duodenoscope\" data-tweet=\"$BSX - FDA clears Boston Scientific single-use duodenoscope https://seekingalpha.com/news/3526245-fda-clears-boston-scientific-single-use-duodenoscope?source=tweet\" data-url=\"https://seekingalpha.com/news/3526245-fda-clears-boston-scientific-single-use-duodenoscope\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526242\" data-ts=\"1576262003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LKQ\" target=\"_blank\">LKQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526242-lkq-corporation-announces-early-redemption-of-600m-4_75-senior-notes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LKQ Corporation announces early redemption of $600M 4.75% senior notes</a></h4><ul> <li>LKQ Corporation (<a href='https://seekingalpha.com/symbol/LKQ' title='LKQ Corporation'>LKQ</a> <font color='green'>+0.4%</font>) to <a href=\"https://seekingalpha.com/pr/17727902-lkq-corporation-announces-early-redemption-of-600-million-4_75-senior-notes\" target=\"_blank\">redeem</a> its $600M 4.75% Senior Notes due 2023 on January 10, 2020 at a price equal to 101.583% of the principal amount of the Notes plus accrued and unpaid interest.</li><li>Redemption is subject to the Company having sufficient financing available on the redemption date to pay the redemption price.</li>       </ul><div class=\"tiny-share-widget\" data-id=\"3526242\" data-linked=\"LKQ Corporation announces early redemption of $600M 4.75% senior notes\" data-tweet=\"$LKQ - LKQ Corporation announces early redemption of $600M 4.75% senior notes https://seekingalpha.com/news/3526242-lkq-corporation-announces-early-redemption-of-600m-4_75-senior-notes?source=tweet\" data-url=\"https://seekingalpha.com/news/3526242-lkq-corporation-announces-early-redemption-of-600m-4_75-senior-notes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526235\" data-ts=\"1576260678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526235-cohn-leads-financial-gainers-opi-and-mtr-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">COHN leads financial gainers; OPI and MTR the only losers</a></h4><ul><li><b>Gainers:</b> Cohen &amp; Company (NYSEMKT:<a href='https://seekingalpha.com/symbol/COHN' title='Cohen & Company Inc.'>COHN</a>) <font color=\"green\">+25%</font>. China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+12%</font>. The Royal Bank of Scotland Group (NYSE:<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>) <font color=\"green\">+10%</font>. China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance Limited'>XRF</a>) <font color=\"green\">+10%</font>. Banco BBVA Argentina (NYSE:<a href='https://seekingalpha.com/symbol/BBAR' title='Banco BBVA Argentina S.A.'>BBAR</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers:</b> At Home Group (NYSE:<a href='https://seekingalpha.com/symbol/HOME' title='At Home Group Inc.'>HOME</a>) <font color=\"red\">-10%</font>. Mesa Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/MTR' title='Mesa Royalty Trust'>MTR</a>) <font color=\"red\">-7%</font>. Office Properties Income Trust (NASDAQ:<a href='https://seekingalpha.com/symbol/OPI' title='Office Properties Income Trust'>OPI</a>) <font color=\"red\">-7%</font>. FinVolution Group (NYSE:<a href='https://seekingalpha.com/symbol/FINV' title='FinVolution Group'>FINV</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526235\" data-linked=\"COHN leads financial gainers; OPI and MTR the only losers\" data-tweet=\"$COHN $CIFS $RBS - COHN leads financial gainers; OPI and MTR the only losers https://seekingalpha.com/news/3526235-cohn-leads-financial-gainers-opi-and-mtr-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526235-cohn-leads-financial-gainers-opi-and-mtr-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526234\" data-ts=\"1576260657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMRN\" target=\"_blank\">AMRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526234-amarin-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amarin shares halted pending news</a></h4><ul><li>Nasdaq has suspended trading in Amarin (<a href='https://seekingalpha.com/symbol/AMRN' title='Amarin Corporation plc'>AMRN</a> <font color='green'>+4.9%</font>) pending the release of news. In this, probably the expected FDA nod for a CV benefit claim for Vascepa (icosapent ethyl). The agency's action date is December 28.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526234\" data-linked=\"Amarin shares halted pending news\" data-tweet=\"$AMRN - Amarin shares halted pending news https://seekingalpha.com/news/3526234-amarin-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3526234-amarin-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>183&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526230\" data-ts=\"1576260067\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526230-arcosa-only-industrial-gainer-hovnanian-enterprises-leads-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arcosa only industrial gainer; Hovnanian Enterprises leads the losers</a></h4><ul><li><b>Gainers: </b>Arcosa (NYSE:<a href='https://seekingalpha.com/symbol/ACA' title='Arcosa, Inc.'>ACA</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>Hovnanian Enterprises (NYSE:<a href='https://seekingalpha.com/symbol/HOV' title='Hovnanian Enterprises, Inc.'>HOV</a>) <font color=\"red\">-8%</font>. Babcock &amp; Wilcox (NYSE:<a href='https://seekingalpha.com/symbol/BW' title='Babcock & Wilcox Enterprises, Inc.'>BW</a>) <font color=\"red\">-8%</font>. Granite Construction (NYSE:<a href='https://seekingalpha.com/symbol/GVA' title='Granite Construction Incorporated'>GVA</a>) <font color=\"red\">-6%</font>. Shiloh Industries (NASDAQ:<a href='https://seekingalpha.com/symbol/SHLO' title='Shiloh Industries, Inc.'>SHLO</a>) <font color=\"red\">-6%</font>. BioHiTech Global (NASDAQ:<a href='https://seekingalpha.com/symbol/BHTG' title='BioHiTech Global, Inc.'>BHTG</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526230\" data-linked=\"Arcosa only industrial gainer; Hovnanian Enterprises leads the losers\" data-tweet=\"$ACA $HOV $BW - Arcosa only industrial gainer; Hovnanian Enterprises leads the losers https://seekingalpha.com/news/3526230-arcosa-only-industrial-gainer-hovnanian-enterprises-leads-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526230-arcosa-only-industrial-gainer-hovnanian-enterprises-leads-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526231\" data-ts=\"1576260044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526231-rosenblatt-doesnt-expect-apple-win-for-synaptics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rosenblatt doesn&#39;t expect Apple win for Synaptics</a></h4><ul><li>Rosenblatt <a href=\"https://seekingalpha.com/news/3526140-synaptics-raised-on-suspected-apple-win\" target=\"_blank\">disagrees</a> with Susquehanna, which said Broadcom's earnings report suggested an Apple win for Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>)</li><li>Analyst Jun Zhang expects Apple to use Samsung tech instead since Samsung is offering \"a very competitive price\" to encourage the adoption.</li><li>Zhang expects SYNA's LCD driver business at Apple to decline over 2020 and sees no growth as the best-case scenario.</li><li>Synaptics shares are <font color=\"green\">up 7.9%</font> to $64.04.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526231\" data-linked=\"Rosenblatt doesn&#39;t expect Apple win for Synaptics\" data-tweet=\"$SYNA - Rosenblatt doesn&#39;t expect Apple win for Synaptics https://seekingalpha.com/news/3526231-rosenblatt-doesnt-expect-apple-win-for-synaptics?source=tweet\" data-url=\"https://seekingalpha.com/news/3526231-rosenblatt-doesnt-expect-apple-win-for-synaptics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526227\" data-ts=\"1576259474\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VIAC\" target=\"_blank\">VIAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526227-bofa-bullish-on-viacomcbs-content-catalysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA bullish on ViacomCBS content, catalysts</a></h4><ul><li>Bank of America reinstates ViacomCBS (NASDAQ:<a href='https://seekingalpha.com/symbol/VIAC' title='ViacomCBS Inc.'>VIAC</a>) with a Buy rating and $60 price target.</li><li>Analyst Jessica Reif Ehrlich cites the potential to outperform due to the combined entity's proven brands, pay-TV scale, growing direct-to-consumer business, and large content library. The analyst sees the potential for VIAC to see $500M+ in run rate cost synergies by CY21.</li><li>BofA sees near-term catalysts in affiliate and retransmission renewals, a potential investor day, the 2020-21 upfronts, and potential buybacks.</li><li>VIAC shares are <font color=\"green\">up 1.5%</font> to $38.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526227\" data-linked=\"BofA bullish on ViacomCBS content, catalysts\" data-tweet=\"$VIAC - BofA bullish on ViacomCBS content, catalysts https://seekingalpha.com/news/3526227-bofa-bullish-on-viacomcbs-content-catalysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3526227-bofa-bullish-on-viacomcbs-content-catalysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526226\" data-ts=\"1576259044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526226-srpt-trxc-oncs-and-cei-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SRPT, TRXC, ONCS and CEI among midday movers</a></h4><ul><li><strong>Gainers: </strong>LMP Automotive (NASDAQ:<a href='https://seekingalpha.com/symbol/LMPX' title='LMP Automotive Holdings, Inc.'>LMPX</a>) <font color=\"green\">+95%</font>.</li><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"green\">+35%</font>.</li><li>Cohen &amp; Company (NYSEMKT:<a href='https://seekingalpha.com/symbol/COHN' title='Cohen & Company Inc.'>COHN</a>) <font color=\"green\">+25%</font>.</li><li>Salarius Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SLRX' title='Salarius Pharmaceuticals, Inc.'>SLRX</a>) <font color=\"green\">+19%</font>.</li><li>Emmaus Life Sciences (<a href='https://seekingalpha.com/symbol/EMMA' title='Emmaus Life Sciences, Inc.'>OTC:EMMA</a>) <font color=\"green\">+18%</font>.</li><li>Satsuma Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/STSA' title='Satsuma Pharmaceuticals, Inc.'>STSA</a>) <font color=\"green\">+17%</font>.</li><li>AdaptHealth (NASDAQ:<a href='https://seekingalpha.com/symbol/AHCO' title='AdaptHealth Corp.'>AHCO</a>) <font color=\"green\">+15%</font>.</li><li>scPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SCPH' title='scPharmaceuticals Inc.'>SCPH</a>) <font color=\"green\">+13%</font>.</li><li>Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"green\">+14%</font>.</li><li>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+13%</font>.</li><li><strong>Losers:</strong> Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"red\">-45%</font>.</li><li>Vince Holding (NYSE:<a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a>) <font color=\"red\">-22%</font>.</li><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"red\">-19%</font>.</li><li>Gridsum (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding Inc.'>GSUM</a>) <font color=\"red\">-19%</font>.</li><li>Stage Stores (NYSE:<a href='https://seekingalpha.com/symbol/SSI' title='Stage Stores, Inc.'>SSI</a>) <font color=\"red\">-17%</font>.</li><li>Athenex (NASDAQ:<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a>) <font color=\"red\">-17%</font>.</li><li>OncoSec Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a>) <font color=\"red\">-16%</font>.</li><li>TransEnterix (NYSEMKT:<a href='https://seekingalpha.com/symbol/TRXC' title='TransEnterix, Inc.'>TRXC</a>) <font color=\"red\">-14%</font>.</li><li>Anixa Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ANIX' title='Anixa Biosciences, Inc.'>ANIX</a>) <font color=\"red\">-14%</font>.</li><li>Good Times Restaurants (NASDAQ:<a href='https://seekingalpha.com/symbol/GTIM' title='Good Times Restaurants Inc.'>GTIM</a>) <font color=\"red\">-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526226\" data-linked=\"SRPT, TRXC, ONCS and CEI among midday movers\" data-tweet=\"$LMPX $SRPT $COHN - SRPT, TRXC, ONCS and CEI among midday movers https://seekingalpha.com/news/3526226-srpt-trxc-oncs-and-cei-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526226-srpt-trxc-oncs-and-cei-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526223\" data-ts=\"1576257039\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526223-transocean-up-4-on-new-91m-contract\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean up 4% on new $91M contract</a></h4><ul><li>Transocean Ltd. (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color=\"green\">+3.7%</font>) is up on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17727348-transocean-ltd-announces-contract-award-for-development-driller-iii\" target=\"_blank\">announcement </a>that the semisubmersible <em>Development Driller III</em> has bagged a one-year contract off the coast of Trinidad and Tobago, expected to start in Q2 2020, that should add ~$91M of backlog (excluding mobilization reimbursement).</li></ul><div class=\"tiny-share-widget\" data-id=\"3526223\" data-linked=\"Transocean up 4% on new $91M contract\" data-tweet=\"$RIG - Transocean up 4% on new $91M contract https://seekingalpha.com/news/3526223-transocean-up-4-on-new-91m-contract?source=tweet\" data-url=\"https://seekingalpha.com/news/3526223-transocean-up-4-on-new-91m-contract\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526220\" data-ts=\"1576256531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TNDM\" target=\"_blank\">TNDM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526220-fda-oks-tandems-control-iq-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs Tandem&#39;s Control-IQ; shares up 1%</a></h4><ul><li>Tandem Diabetes Care (<a href='https://seekingalpha.com/symbol/TNDM' title='Tandem Diabetes Care, Inc.'>TNDM</a> <font color=\"green\">+0.8%</font>) perks up on below-average volume on the heels of the <a href=\"https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-allow-more-choices\" target=\"_blank\">FDA nod</a> for its Control-IQ, a controller that automatically adjusts insulin delivery via the integration of an insulin pump (the t:slim X2) and continuous glucose monitor (DexCom's (<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a> <font color=\"green\">+0.3%</font>) G6).</li></ul><div class=\"tiny-share-widget\" data-id=\"3526220\" data-linked=\"FDA OKs Tandem&#39;s Control-IQ; shares up 1%\" data-tweet=\"$TNDM $DXCM - FDA OKs Tandem&#39;s Control-IQ; shares up 1% https://seekingalpha.com/news/3526220-fda-oks-tandems-control-iq-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3526220-fda-oks-tandems-control-iq-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526219\" data-ts=\"1576256467\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526219-nio-and-cresud-among-consumer-gainers-adient-and-vince-holding-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NIO and Cresud among consumer gainers; Adient and Vince Holding among losers</a></h4><ul><li><b>Gainers: </b>Embotelladora Andina (NYSE:<a href='https://seekingalpha.com/symbol/AKO.A' title='Embotelladora Andina S.A.'>AKO.A</a>) <font color=\"green\">+10%</font>. NIO (NYSE:<a href='https://seekingalpha.com/symbol/NIO' title='NIO Limited'>NIO</a>) <font color=\"green\">+6%</font>. Cresud (NASDAQ:<a href='https://seekingalpha.com/symbol/CRESY' title='Cresud Sociedad Anónima Comercial, Inmobiliaria, Financiera y Agropecuaria'>CRESY</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Vince Holding (NYSE:<a href='https://seekingalpha.com/symbol/VNCE' title='Vince Holding Corp.'>VNCE</a>) <font color=\"red\">-17%</font>. The Lovesac (NASDAQ:<a href='https://seekingalpha.com/symbol/LOVE' title='The Lovesac Company'>LOVE</a>) <font color=\"red\">-10%</font>. Farmmi (NASDAQ:<a href='https://seekingalpha.com/symbol/FAMI' title='Farmmi, Inc.'>FAMI</a>) <font color=\"red\">-9%</font>. Viomi Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/VIOT' title='Viomi Technology Co., Ltd'>VIOT</a>) <font color=\"red\">-6%</font>. Adient (NYSE:<a href='https://seekingalpha.com/symbol/ADNT' title='Adient plc'>ADNT</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526219\" data-linked=\"NIO and Cresud among consumer gainers; Adient and Vince Holding among losers\" data-tweet=\"$AKO.A $NIO $CRESY - NIO and Cresud among consumer gainers; Adient and Vince Holding among losers https://seekingalpha.com/news/3526219-nio-and-cresud-among-consumer-gainers-adient-and-vince-holding-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526219-nio-and-cresud-among-consumer-gainers-adient-and-vince-holding-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526217\" data-ts=\"1576256306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FFIV\" target=\"_blank\">FFIV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526217-f5-networksminus-2-after-russian-police-raid-subsidiary\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">F5 Networks -2% after Russian police raid subsidiary</a></h4><ul><li>F5 Networks (NASDAQ:<a href='https://seekingalpha.com/symbol/FFIV' title='F5 Networks, Inc.'>FFIV</a>) <font color=\"red\">slides 2.2%</font> after yesterday's <a href=\"https://www.zdnet.com/article/russian-police-raid-nginx-moscow-office/\" target=\"_blank\">ZDNet report </a>that Russian police raided the offices of subsidiary NGINX. The authorities reportedly seized equipment and questioned employees.</li><li>Last week, Rambler Group filed a copyright violation that claimed full ownership of NGINX's web server code. Rambler Group owns one of Russia's largest search engines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526217\" data-linked=\"F5 Networks -2% after Russian police raid subsidiary\" data-tweet=\"$FFIV - F5 Networks -2% after Russian police raid subsidiary https://seekingalpha.com/news/3526217-f5-networksminus-2-after-russian-police-raid-subsidiary?source=tweet\" data-url=\"https://seekingalpha.com/news/3526217-f5-networksminus-2-after-russian-police-raid-subsidiary\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526216\" data-ts=\"1576256169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PWCDF\" target=\"_blank\">PWCDF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526216-power-financial-soars-9_9-after-restructuring-announced\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Power Financial soars 9.9% after restructuring announced</a></h4><ul><li>Power Financial (<a href='https://seekingalpha.com/symbol/POFNF' title='Power Financial Corporation'>OTCPK:POFNF</a>) <font color=\"green\">surges 9.9% </font>and Power Corporation of Canada (<a href='https://seekingalpha.com/symbol/PWCDF' title='Power Corporation of Canada'>OTCPK:PWCDF</a>) jumps 7.7% after they <a href=\"https://seekingalpha.com/pr/17727610-power-corporation-and-power-financial-announce-reorganization-simplified-corporate-structure\" target=\"_blank\">unveil a plan</a> to eliminate their dual-holding company structure, cut costs, and boost the resulting company's dividend.</li><li>Power Financial minority shareholders will get 1.05 Power Corporation subordinate voting shares and nominal cash consideration for each Power Financial common share.</li><li>They'll also get Power Corporation shares with net asset value that is C$4.50 (US$3.41) higher than the NAV of each Power Financial common share.</li><li>Plans to boost Power Corporation's quarterly dividend by 10% to C$0.4475 per share starting in Q2 2020.</li><li>As part of the changes, Paul Desmarais Jr. and André Desmarais will retire as Co-CEOs but will continue to serve as chairman and deputy chairman, respectively.</li><li>R. Jeffrey Orr, president and CEO of Power Financial, will become president and CEO of Power Corporation.</li><li>Pansolo Holding, a holding company controlled by the Desmarais Family Residuary Trust, will retain control of Power Corporation after the restructuring.</li><li>Power Corporation expects near-term cost reductions of ~C$50M per year within two years; Power Corporation and Power Financial plan to redeem a total of C$350M of first preferred shares with available cash, resulting in reduced annual financing costs of ~$15M per year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526216\" data-linked=\"Power Financial soars 9.9% after restructuring announced\" data-tweet=\"$PWCDF $POFNF $POFNF - Power Financial soars 9.9% after restructuring announced https://seekingalpha.com/news/3526216-power-financial-soars-9_9-after-restructuring-announced?source=tweet\" data-url=\"https://seekingalpha.com/news/3526216-power-financial-soars-9_9-after-restructuring-announced\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526214\" data-ts=\"1576255261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIBN\" target=\"_blank\">SIBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526214-si-bone-up-6-on-new-coverage-of-ifuse-implant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SI-BONE up 6% on new coverage of iFuse implant</a></h4><ul><li>Thinly traded SI-BONE (<a href='https://seekingalpha.com/symbol/SIBN' title='SI-BONE, Inc.'>SIBN</a> <font color=\"green\">+6.3%</font>) is up on double normal volume, a modest 237K shares, in response to Cigna's decision to cover minimally invasive sacroiliac &#40;SI&#41; joint fusion exclusively for implants that are placed across the SI joint to promote bone fusion, like the company's <a href=\"https://si-bone.com/si-joint-pain-treatment/ifuse-implant-system\" target=\"_blank\">iFuse Implant System</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526214\" data-linked=\"SI-BONE up 6% on new coverage of iFuse implant\" data-tweet=\"$SIBN - SI-BONE up 6% on new coverage of iFuse implant https://seekingalpha.com/news/3526214-si-bone-up-6-on-new-coverage-of-ifuse-implant?source=tweet\" data-url=\"https://seekingalpha.com/news/3526214-si-bone-up-6-on-new-coverage-of-ifuse-implant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:41 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526209\" data-ts=\"1576254282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCS\" target=\"_blank\">ONCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526209-oncosec-medical-down-13-despite-positive-tova-data-in-tnbc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoSec Medical down 13% despite positive TOVA data in TNBC</a></h4><ul><li>Thinly traded nano cap OncoSec Medical (<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color=\"red\">-12.9%</font>) is down, albeit on below-average volume, on the heels of <a href=\"https://seekingalpha.com/pr/17727758-oncosec-presents-interim-data-of-28_5-objective-response-rate-orr-from-ongoing-keynoteminus\" target=\"_blank\">interim data</a> from a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03567720?term=keynote-890&amp;draw=2&amp;rank=1\" target=\"_blank\">KEYNOTE-890</a>, evaluating the combination of TAVO (intratumoral IL-12) and Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co., Inc.'>MRK</a> <font color=\"red\">-0.4%</font>) Keytruda (pembrolizumab) in patients with metastatic chemo-refractory triple negative breast cancer &#40;TNBC&#41;. The results were presented at the San Antonio Breast Cancer Symposium.</li><li>At data cutoff, the partial response rate was 29% (n=4/14). Median duration of response had not been reached. Stable cancer was observed in three participants, implying a disease control rate of 50% (n=7/14). Seven patients progressed.</li><li>By comparison, a Phase 3 study, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02555657?term=NCT02555657&amp;draw=2&amp;rank=1\" target=\"_blank\">KEYNOTE-119</a>, evaluating Keytruda alone compared to chemo in metastatic TNBC patients showed a response rate of 9.4% while another Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02447003?term=keynote-086&amp;draw=2&amp;rank=1\" target=\"_blank\">KEYNOTE-086</a>, showed a 5.3% response rate for Keytruda alone.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526209\" data-linked=\"OncoSec Medical down 13% despite positive TOVA data in TNBC\" data-tweet=\"$ONCS $MRK - OncoSec Medical down 13% despite positive TOVA data in TNBC https://seekingalpha.com/news/3526209-oncosec-medical-down-13-despite-positive-tova-data-in-tnbc?source=tweet\" data-url=\"https://seekingalpha.com/news/3526209-oncosec-medical-down-13-despite-positive-tova-data-in-tnbc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526207\" data-ts=\"1576253987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NIO\" target=\"_blank\">NIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526207-nio-rallies-after-trade-deal-struck\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nio rallies after trade deal struck</a></h4><ul> <li>Nio (<a href='https://seekingalpha.com/symbol/NIO' title='NIO Limited'>NIO</a> <font color='green'>+4.6%</font>) breaks higher after China and the U.S. announce a trade deal has been struck (although details were limited).</li><li>The optimism could be tied closer to what the trade war cooling will mean for the Chinese economy.</li> <li>Earlier this week, Nio received goods news from Beijing when the Chinese government said it's lifting its 2025 sales target for electric cars.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526207\" data-linked=\"Nio rallies after trade deal struck\" data-tweet=\"$NIO - Nio rallies after trade deal struck https://seekingalpha.com/news/3526207-nio-rallies-after-trade-deal-struck?source=tweet\" data-url=\"https://seekingalpha.com/news/3526207-nio-rallies-after-trade-deal-struck\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526206\" data-ts=\"1576253108\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HHC\" target=\"_blank\">HHC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526206-ackman-gets-waiver-to-boost-howard-hughes-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ackman gets a waiver to boost Howard Hughes stake</a></h4><ul><li>Howard Hughes Corp. (NYSE:<a href='https://seekingalpha.com/symbol/HHC' title='The Howard Hughes Corporation'>HHC</a>)<font color=\"green\"> gains 1.7%</font> after the board grants a waiver to Bill Ackman's Pershing Square to acquire up to 26% of its stock.</li><li>According to a filing, Pershing Square holds a 14.8% stake in HHC, which is unchanged from a Dec. 4 filing.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526206\" data-linked=\"Ackman gets a waiver to boost Howard Hughes stake\" data-tweet=\"$HHC - Ackman gets a waiver to boost Howard Hughes stake https://seekingalpha.com/news/3526206-ackman-gets-waiver-to-boost-howard-hughes-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3526206-ackman-gets-waiver-to-boost-howard-hughes-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526203\" data-ts=\"1576252942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526203-sarepta-therapeutics-leads-healthcare-gainers-oncosec-medical-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta Therapeutics leads healthcare gainers; OncoSec Medical among losers</a></h4><ul><li><b>Gainers: </b>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"green\">+33%</font>. Salarius Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SLRX' title='Salarius Pharmaceuticals, Inc.'>SLRX</a>) <font color=\"green\">+22%</font>. Emmaus Life Sciences (<a href='https://seekingalpha.com/symbol/EMMA' title='Emmaus Life Sciences, Inc.'>OTC:EMMA</a>) <font color=\"green\">+18%</font>. TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <font color=\"green\">+11%</font>. CTI BioPharma (NASDAQ:<a href='https://seekingalpha.com/symbol/CTIC' title='CTI BioPharma Corp.'>CTIC</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) <font color=\"red\">-45%</font>. Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"red\">-20%</font>. Assembly Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ASMB' title='Assembly Biosciences, Inc.'>ASMB</a>) <font color=\"red\">-14%</font>. OncoSec Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a>) <font color=\"red\">-14%</font>. Avalon GloboCare (NASDAQ:<a href='https://seekingalpha.com/symbol/AVCO' title='Avalon GloboCare Corp.'>AVCO</a>) <font color=\"red\">-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526203\" data-linked=\"Sarepta Therapeutics leads healthcare gainers; OncoSec Medical among losers\" data-tweet=\"$SRPT $SLRX $EMMA - Sarepta Therapeutics leads healthcare gainers; OncoSec Medical among losers https://seekingalpha.com/news/3526203-sarepta-therapeutics-leads-healthcare-gainers-oncosec-medical-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526203-sarepta-therapeutics-leads-healthcare-gainers-oncosec-medical-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526201\" data-ts=\"1576252559\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526201-stocks-erase-gains-after-u-s-china-trade-pact-pop\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stocks erase gains after U.S.-China trade pact pop</a></h4><ul><li>The three major U.S. stock averages fade as investors weigh the latest information from the U.S.-China phase one trade pact.</li><li>The S&amp;P 500 <font color=\"red\">slips 0.1%</font>; the Nasdaq, which had risen as much as 0.6%, clings onto a<font color=\"green\"> 0.1% gain</font>; and the Dow's earlier 0.6% advance vanishes to flat.</li><li>10-year Treasury rallies, pushing yield down 6 basis points to 1.83%.</li><li>The U.S. Trade Representative said<a href=\"https://ustr.gov/about-us/policy-offices/press-office/press-releases/2019/december/united-states-and-china-reach\" target=\"_blank\"> it will keep </a>25% tariffs on $250B of Chinese imports and 7.5% tariffs on $120B of Chinese goods.</li><li>Tariffs that were due to take effect on Sunday are suspended.</li><li>Other than those numbers, though, few details were disclosed. President Trump tweeted that the <a href=\"https://twitter.com/realDonaldTrump/status/1205509125788098560\" target=\"_blank\">phase one deal cover</a>s \"many structural changes changes\", without being more specific. And Chinese officials declined to give a number on the amount of U.S. agricultural purchases they agreed to make.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3526195-stocks-bounce-up-after-china-confirms-trade-deal-u-s-updated\" target=\"_blank\">Stocks bounce up after China confirms trade deal with U.S. (updated)</a> (Dec. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526201\" data-linked=\"Stocks erase gains after U.S.-China trade pact pop\" data-tweet=\"Stocks erase gains after U.S.-China trade pact pop https://seekingalpha.com/news/3526201-stocks-erase-gains-after-u-s-china-trade-pact-pop?source=tweet\" data-url=\"https://seekingalpha.com/news/3526201-stocks-erase-gains-after-u-s-china-trade-pact-pop\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>165&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526198\" data-ts=\"1576251164\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANIX\" target=\"_blank\">ANIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526198-anixa-bio-down-16-on-extended-timeline-for-car-t-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anixa Bio down 16% on extended timeline for CAR T candidate</a></h4><ul><li>Thinly traded nano cap Anixa Biosciences (<a href='https://seekingalpha.com/symbol/ANIX' title='Anixa Biosciences, Inc.'>ANIX</a> <font color=\"red\">-16.4%</font>) is down more on than triple normal volume, albeit on turnover of only 165K shares, in apparent response to a <a href=\"https://seekingalpha.com/pr/17727635-anixa-biosciences-provides-update-on-car-t-program\" target=\"_blank\">longer development timeline</a> for a CAR T therapy it is developing with Moffitt Cancer Center designed to express follicle stimulating hormone &#40;FSH&#41; for the potential treatment of FSH receptor-expressing cancers.</li><li>Recent experiments showed that additional engineering may enable the transformed cells to significantly increase FSH expression so the decision has been made to pursue the opportunity, an effort expected to take as long as a year. Consequently, an IND will not be filed until late 2020 with clinical trials to commence in 2021.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526198\" data-linked=\"Anixa Bio down 16% on extended timeline for CAR T candidate\" data-tweet=\"$ANIX - Anixa Bio down 16% on extended timeline for CAR T candidate https://seekingalpha.com/news/3526198-anixa-bio-down-16-on-extended-timeline-for-car-t-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3526198-anixa-bio-down-16-on-extended-timeline-for-car-t-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526197\" data-ts=\"1576250921\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526197-apple-semis-gain-on-trade-text-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Apple, semis gain on trade text deal</a></h4><ul><li>Apple (NASDAQ:<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a>) <font color=\"green\">gains 1%</font> and the Philadelphia Semiconductor Index is <font color=\"green\">up 0.6%</font> after Chinese officials <a href=\"https://www.cnbc.com/2019/12/12/stocks-are-set-to-add-to-thursdays-rally-as-us-and-china-near-signing-of-trade-deal.html\" target=\"_blank\">confirmed</a> reaching an agreement on the text of the phase one U.S. trade deal.</li><li>Officials say the tariffs will be rolled back in phases.</li><li>There are still some legal logistics to complete on both sides before finalizing the deal.</li><li>The tech sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) is <font color=\"green\">up 0.7%</font>.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Exchange-Traded Fund Trust - Invesco Dynamic Semiconductors ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Exchange-Traded Fund VI - First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526197\" data-linked=\"Apple, semis gain on trade text deal\" data-tweet=\"$AAPL $XLK $SOXL - Apple, semis gain on trade text deal https://seekingalpha.com/news/3526197-apple-semis-gain-on-trade-text-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3526197-apple-semis-gain-on-trade-text-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526189\" data-ts=\"1576249608\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SLRX\" target=\"_blank\">SLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526189-salarius-pharma-up-15-ahead-of-seclidemstat-study-presentation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salarius Pharma up 15% ahead of seclidemstat study presentation</a></h4><ul><li>Thinly traded nano cap Salarius Pharmaceuticals (<a href='https://seekingalpha.com/symbol/SLRX' title='Salarius Pharmaceuticals, Inc.'>SLRX</a> <font color=\"green\">+15%</font>) is up on almost 50% higher volume, a modest 37K shares, in apparent response to its <a href=\"https://seekingalpha.com/pr/17726521-salarius-pharmaceuticals-to-present-trial-in-progress-poster-epigenetics-symposium-15-years\" target=\"_blank\">announcement </a>that an overview of its <a href=\"https://clinicaltrials.gov/ct2/show/NCT03600649?lead=salarius+pharmaceuticals&amp;draw=2&amp;rank=2\" target=\"_blank\">Phase 1/2 clinical trial</a> evaluating lead drug seclidemstat in patients with a rare pediatric bone cancer called <a href=\"https://www.mayoclinic.org/diseases-conditions/ewing-sarcoma/symptoms-causes/syc-20351071\" target=\"_blank\">Ewing sarcoma</a> will be presented on Monday, December 16, at the Epigenetics Symposium in Philadelphia.</li><li><a href=\"http://salariuspharma.com/our-programs/pipeline/\" target=\"_blank\">Seclidemstat</a> is a small molecule inhibitor of an epigenetic enzyme called lysine-specific demethylase 1 (LSD1), highly expressed in certain cancers and associated with aggressive disease and poor prognosis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526189\" data-linked=\"Salarius Pharma up 15% ahead of seclidemstat study presentation\" data-tweet=\"$SLRX - Salarius Pharma up 15% ahead of seclidemstat study presentation https://seekingalpha.com/news/3526189-salarius-pharma-up-15-ahead-of-seclidemstat-study-presentation?source=tweet\" data-url=\"https://seekingalpha.com/news/3526189-salarius-pharma-up-15-ahead-of-seclidemstat-study-presentation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526190\" data-ts=\"1576249074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SKX\" target=\"_blank\">SKX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526190-argus-sees-value-in-skechers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argus sees value in Skechers</a></h4><ul> <li>Argus lifts its rating on Skechers (<a href='https://seekingalpha.com/symbol/SKX' title='Skechers U.S.A., Inc.'>SKX</a> <font color='green'>+0.8%</font>) to Buy from Neutral as it points to robust global demand for the retailer's products.</li> <li>\"Given prospects for sustained revenue growth and margin improvement, we believe that the shares are undervalued at 16.5-times our revised 2020 earnings estimate and are setting a price target of $50,\" writes analyst John Staszak. The Argus PT is ahead of the <a href=\"https://seekingalpha.com/symbol/SKX/ratings/sell-side-ratings\" target=\"_blank\">average price target</a> of $44.00.</li> <li>Argus also has a five-year Buy rating on SKX on top of the traditional one-year view.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526190\" data-linked=\"Argus sees value in Skechers\" data-tweet=\"$SKX - Argus sees value in Skechers https://seekingalpha.com/news/3526190-argus-sees-value-in-skechers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526190-argus-sees-value-in-skechers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526188\" data-ts=\"1576248787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526188-pot-names-mull-ontario-retail-opening-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pot names mull Ontario retail opening news</a></h4><ul><li><a href=\"https://www.marketwatch.com/story/cannabis-stocks-rally-out-of-the-gate-on-report-ontario-to-open-market-for-store-openings-2019-12-13?mod=mw_latestnews\" target=\"_blank\">Canada's CBC reports</a> Ontario plans to issue about 20 new store approvals beginning next April. The story comes amid concerns that a shortage of retail outlets is getting in the way of the development of a legal market for pot.</li><li>The illegal market for cannabis still has about an 80% share in Canada, according to MKM's Bill Kirk, who was hoping for a number of openings far higher than 20.</li><li>Canopy Growth (<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a> <font color=\"green\">+1.3%</font>), Aurora Cannabis (<a href='https://seekingalpha.com/symbol/ACB' title='Aurora Cannabis Inc.'>ACB</a> <font color=\"green\">+0.4%</font>), Cronos Group (<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group Inc.'>CRON</a> <font color=\"red\">-1.4%</font>), Tilray (<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"red\">-0.3%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526188\" data-linked=\"Pot names mull Ontario retail opening news\" data-tweet=\"$CGC $ACB $CRON - Pot names mull Ontario retail opening news https://seekingalpha.com/news/3526188-pot-names-mull-ontario-retail-opening-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3526188-pot-names-mull-ontario-retail-opening-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>56&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526185\" data-ts=\"1576248513\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATNX\" target=\"_blank\">ATNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526185-athenex-down-17-on-oral-paclitaxel-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Athenex down 17% on oral paclitaxel data</a></h4><ul><li><a href=\"https://www.abstractsonline.com/pp8/#!/7946/presentation/2050\" target=\"_blank\">Results</a> from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02594371?lead=athenex&amp;phase=2&amp;draw=2&amp;rank=3\" target=\"_blank\">Phase 3 clinical trial</a> comparing Athenex's (<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a> <font color=\"red\">-17.4%</font>) oral paclitaxel (and oral absorption technology encequidar) to the intravenous &#40;IV&#41; formulation in metastatic breast cancer patients showed superior response and survival but with a mixed safety profile. The data are being presented at the San Antonio Breast Cancer Symposium.</li><li>In the intent-to-treat population, the tumor response rate in the oral paclitaxel group was 35.8% (n=95/265) versus 23.4% (n=32/137) (p=0.011). In the population with evaluable post-baseline scan, the response rates were 50.3% and 29.6%, respectively (p=0.0005). Median duration of response was greater in the oral group (27.9 months) compared to the IV group (16.9 months).</li><li>Median overall survival &#40;OS&#41; was 27.9 months compared to 16.9 months for IV paclitaxel (p=0.035).</li><li>Median progression-free survival favored oral paclitaxel, 9.3 months vs. 8.3 months, but the separation thus far was not statistically significant (p=0.077).</li><li>Investors appear to be reacting to the safety data. The rates of alopecia (hair loss), severity of neuropathic adverse events (17% vs. 57%) and serious neuropathic symptoms (1% vs. 8%) were lower in patients receiving oral paclitaxel, but higher rates of neutropenia, infection and gastrointestinal adverse events were observed. The toxicity profiles of oral and IV pactlitaxel were generally similar.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526185\" data-linked=\"Athenex down 17% on oral paclitaxel data\" data-tweet=\"$ATNX - Athenex down 17% on oral paclitaxel data https://seekingalpha.com/news/3526185-athenex-down-17-on-oral-paclitaxel-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3526185-athenex-down-17-on-oral-paclitaxel-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526182\" data-ts=\"1576247777\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526182-christmas-came-early-for-adobe-earnings-analysts\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">&#39;Christmas came early&#39; for Adobe earnings - analysts</a></h4><ul><li>Jefferies rates Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Inc.'>ADBE</a>) at Buy and raises the target from $350 to $370.</li><li>Analyst Brent Thill says that \"Christmas came early\" with yesterday's <a href=\"https://seekingalpha.com/news/3526001-adobeplus-3_3-after-q4-beats\" target=\"_blank\">Q4 beats</a>.</li><li>Thill says the FY20 outlook now looks conservative and that \"star performer\" Digital Media \"shows no signs of fading.\"</li><li>Wedbush's Daniel Ives remains on the Adobe sidelines and raises the target from $290 to $315.</li><li>Ives sees relatively healthy demand trends for ADBE's creative solutions and no major hurdles ahead for the broader fundamentals.</li><li>The analyst notes a lingering concern with Adobe proving its B2B success with the Marketo and Magento deals.</li><li>Adobe shares are <font color=\"green\">up 3.6%</font> to $317.09. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/ADBE/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526182\" data-linked=\"&#39;Christmas came early&#39; for Adobe earnings - analysts\" data-tweet=\"$ADBE - &#39;Christmas came early&#39; for Adobe earnings - analysts https://seekingalpha.com/news/3526182-christmas-came-early-for-adobe-earnings-analysts?source=tweet\" data-url=\"https://seekingalpha.com/news/3526182-christmas-came-early-for-adobe-earnings-analysts\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526179\" data-ts=\"1576247289\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526179-wsj-no-deal-trump-fake-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: No deal; Trump: That&#39;s fake news</a></h4><ul><li>While the administration has been touting that a deal has been reached, China is not confirming as much, <a href=\"https://www.wsj.com/articles/china-offers-no-confirmation-on-u-s-trade-deal-11576234325?mod=hp_lead_pos3\" target=\"_blank\">reports the <em>WSJ</em></a>.</li><li>The president minutes ago <a href=\"https://twitter.com/realDonaldTrump/status/1205489214546235393\" target=\"_blank\">took to Twitter to say</a> that story is wrong, and the<em> Journal </em>needs to find a better leaker.</li><li>Meanwhile, a press conference to talk about this matter is scheduled in Beijing for 9:30 ET.</li><li>Stocks have given back earlier gains, now flat on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526179\" data-linked=\"WSJ: No deal; Trump: That&#39;s fake news\" data-tweet=\"WSJ: No deal; Trump: That&#39;s fake news https://seekingalpha.com/news/3526179-wsj-no-deal-trump-fake-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3526179-wsj-no-deal-trump-fake-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>385&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526176\" data-ts=\"1576246342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526176-aqst-phr-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AQST, PHR among premarket losers</a></h4><ul><li>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>)  <font color=\"red\">-45%</font> on <a href=\"https://seekingalpha.com/news/3526113-aethlon-medical-down-42-premarket-on-pricing-public-offering\" target=\"_blank\">pricing</a> stock offering.</li><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"red\">-20%</font> on <a href=\"https://seekingalpha.com/news/3526049-aquestive-prices-equity-offering-5\" target=\"_blank\">pricing</a> stock offering.</li><li>Tonix Pharmaceuticals Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TNXP' title='Tonix Pharmaceuticals Holding Corp.'>TNXP</a>) <font color=\"red\">-7%</font>.</li><li>Assertio Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/ASRT' title='Assertio Therapeutics, Inc.'>ASRT</a>) <font color=\"red\">-7%</font>.</li><li>Universal Technical Institute (NYSE:<a href='https://seekingalpha.com/symbol/UTI' title='Universal Technical Institute, Inc.'>UTI</a>) <font color=\"red\">-7%</font> on pricing <a href=\"https://seekingalpha.com/news/3526169-universal-technical-institute-prices-secondary-offering\" target=\"_blank\">secondary offering</a>.</li><li>Phreesia (NYSE:<a href='https://seekingalpha.com/symbol/PHR' title='Phreesia, Inc.'>PHR</a>) <font color=\"red\">-6%</font> on <a href=\"https://seekingalpha.com/news/3526089-phreesia-prices-secondary-offering\" target=\"_blank\">pricing</a> secondary offering.</li><li>Athenex (NASDAQ:<a href='https://seekingalpha.com/symbol/ATNX' title='Athenex, Inc.'>ATNX</a>) <font color=\"red\">-5%</font> on <a href=\"https://seekingalpha.com/pr/17727769-athenex-announces-superior-response-and-survival-lower-neuropathy-of-novel-oral-paclitaxel\" target=\"_blank\">announcing</a> oral paclitaxel and encequidar data from Phase III trial.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526176\" data-linked=\"AQST, PHR among premarket losers\" data-tweet=\"$AEMD $AQST $TNXP - AQST, PHR among premarket losers https://seekingalpha.com/news/3526176-aqst-phr-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526176-aqst-phr-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526172\" data-ts=\"1576246187\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526172-jefferies-sees-lyft-small-player-in-car-rental\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies sees Lyft as small player in car rental</a></h4><ul> <li>Hertz Global (NYSE:<a href='https://seekingalpha.com/symbol/HTZ' title='Hertz Global Holdings, Inc.'>HTZ</a>) is <font color=\"green\">up 1.45%</font> in premarket action and Avis Budget (NASDAQ:<a href='https://seekingalpha.com/symbol/CAR' title='Avis Budget Group, Inc.'>CAR</a>) is <font color=\"green\">0.77% higher</font> after Jefferies says the Lyft (NASDAQ:<a href='https://seekingalpha.com/symbol/LYFT' title='Lyft, Inc.'>LYFT</a>) entrance into the car rental business is not a \"big\" negative for the companies.</li> <li>\"Lyft doesn\u2019t have a whole lot of capital so they won\u2019t be able to take this nationwide. They are capital constrained, so I\u2019m not too worried about it,\" stated Jefferies analyst Hamzah Mazari to Bloomberg.</li><li>Jefferies keeps a Buy rating on Hertz and Avis.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3525956-avis-hertz-drop-lyft-rentals-launches\" target=\"_blank\">Avis, Hertz drop as Lyft Rentals launches</a> (Dec. 12)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526172\" data-linked=\"Jefferies sees Lyft as small player in car rental\" data-tweet=\"$HTZ $CAR $LYFT - Jefferies sees Lyft as small player in car rental https://seekingalpha.com/news/3526172-jefferies-sees-lyft-small-player-in-car-rental?source=tweet\" data-url=\"https://seekingalpha.com/news/3526172-jefferies-sees-lyft-small-player-in-car-rental\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526171\" data-ts=\"1576246174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526171-srpt-bcs-among-top-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SRPT, BCS among top gainers</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) <font color=\"green\">+31%</font> on <a href=\"https://seekingalpha.com/news/3526107-sarepta-up-36-premarket-on-fda-nod-for-golodirsen\" target=\"_blank\">FDA nod</a> for golodirsen.</li><li>BioLineRx (NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) <font color=\"green\">+13%</font> on <a href=\"https://seekingalpha.com/news/3526141-biolinerx-up-21-premarket-on-positive-blminus-8040-data\" target=\"_blank\">positive BL-8040 data</a>.</li><li>The Royal Bank of Scotland Group plc (NYSE:<a href='https://seekingalpha.com/symbol/RBS' title='The Royal Bank of Scotland Group plc'>RBS</a>) <font color=\"green\">+12%</font>.</li><li>China Internet Nationwide Financial Services (NASDAQ:<a href='https://seekingalpha.com/symbol/CIFS' title='China Internet Nationwide Financial Services Inc.'>CIFS</a>) <font color=\"green\">+10%</font>.</li><li>ChinaNet Online Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a>) <font color=\"green\">+9%</font>.</li><li>Puma Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) <font color=\"green\">+9%</font>.</li><li>National Grid plc (NYSE:<a href='https://seekingalpha.com/symbol/NGG' title='National Grid plc'>NGG</a>) <font color=\"green\">+9%</font>.</li><li>Barclays PLC (NYSE:<a href='https://seekingalpha.com/symbol/BCS' title='Barclays PLC'>BCS</a>) <font color=\"green\">+8%</font>.</li><li>Lloyds Banking Group plc (NYSE:<a href='https://seekingalpha.com/symbol/LYG' title='Lloyds Banking Group plc'>LYG</a>) <font color=\"green\">+8%</font>.</li><li>Sage Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SAGE' title='Sage Therapeutics, Inc.'>SAGE</a>) <font color=\"green\">+7%</font>.</li><li>Theratechnologies (NASDAQ:<a href='https://seekingalpha.com/symbol/THTX' title='Theratechnologies Inc.'>THTX</a>) <font color=\"green\">+6%</font> as <a href=\"https://seekingalpha.com/pr/17727685-theratechnologies-oncology-platform-improves-efficacy-and-tolerability-of-docetaxel-in-vivo\" target=\"_blank\">Oncology platform improves</a> efficacy and tolerability of Docetaxel in vivo and in vitro.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526171\" data-linked=\"SRPT, BCS among top gainers\" data-tweet=\"$SRPT $BLRX $RBS - SRPT, BCS among top gainers https://seekingalpha.com/news/3526171-srpt-bcs-among-top-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526171-srpt-bcs-among-top-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526170\" data-ts=\"1576245857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526170-toy-stocks-wait-on-beijing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Toy stocks wait on Beijing</a></h4><ul> <li>Mattel (NASDAQ:<a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a>) and Hasbro (NASDAQ:<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>) are pushing higher to follow on yesterday's vibrant tariff relief rally.</li> <li>There were no bumps in the night with the proposed outline for a trade deal and a press conference in Beijing at 9:30 A.M. is upcoming. There's a sense that the toy stocks will go even higher if the presser is positive.</li><li>Mattel is <font color=\"green\">up 2.50%</font> premarket and Hasbro is <font color=\"green\">0.77% higher</font>. Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>) also gained 2.26% yesterday and could see a little upward push again today on trade war cooling.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3526170\" data-linked=\"Toy stocks wait on Beijing\" data-tweet=\"$MAT $HAS $FNKO - Toy stocks wait on Beijing https://seekingalpha.com/news/3526170-toy-stocks-wait-on-beijing?source=tweet\" data-url=\"https://seekingalpha.com/news/3526170-toy-stocks-wait-on-beijing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526169\" data-ts=\"1576245789\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UTI\" target=\"_blank\">UTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526169-universal-technical-institute-prices-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Universal Technical Institute prices secondary offering</a></h4><ul><li>Universal Technical Institute (NYSE:<a href='https://seekingalpha.com/symbol/UTI' title='Universal Technical Institute, Inc.'>UTI</a>) prices secondary offering of ~3.60M shares of the company's common stock by certain selling stockholders affiliated with Coliseum Capital Partners at $6.25/share.</li><li>UTI is not offering any shares in this offering and will not receive any proceeds from the sale of shares in the offering.</li><li>Shares <font color=\"red\">-5%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17727793-universal-technical-institute-prices-secondary-offering\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526169\" data-linked=\"Universal Technical Institute prices secondary offering\" data-tweet=\"$UTI - Universal Technical Institute prices secondary offering https://seekingalpha.com/news/3526169-universal-technical-institute-prices-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526169-universal-technical-institute-prices-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526165\" data-ts=\"1576245675\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526165-biogen-bails-on-gosuranemab-after-failed-mid-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biogen bails on gosuranemab after failed mid-stage study</a></h4><ul><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) has decided to stop development of gosuranemab (BIIB092) after a Phase 2 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03068468?cond=Progressive+Supranuclear+Palsy&amp;lead=biogen&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">PASSPORT</a>, evaluating the N-terminal tau-targeting antibody in patients with progressive supranuclear palsy failed to demonstrate a significant treatment benefit.</li><li>Shares up <font color=\"green\">1%</font> premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526165\" data-linked=\"Biogen bails on gosuranemab after failed mid-stage study\" data-tweet=\"$BIIB - Biogen bails on gosuranemab after failed mid-stage study https://seekingalpha.com/news/3526165-biogen-bails-on-gosuranemab-after-failed-mid-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3526165-biogen-bails-on-gosuranemab-after-failed-mid-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526161\" data-ts=\"1576245419\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STM\" target=\"_blank\">STM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526161-stm-raised-ahead-of-growth-drivers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STM raised ahead of growth drivers</a></h4><ul><li>Cowen maintains an Outperform rating on STMicro (NYSE:<a href='https://seekingalpha.com/symbol/STM' title='STMicroelectronics N.V.'>STM</a>) and raises the target from \u20ac28 to \u20ac31.</li><li>Analyst Matthew Ramsay says STM's new management has navigated a turnaround and thinks the company's Apple exposure is \"unfairly dismissed.\"</li><li>The analyst sees upside potential in the revenue and EPS estimates for 2020 and 2021. Cowen expects a return to sustained high single-digit to low-teen growth rate.</li><li>STM's US-listed shares are <font color=\"green\">up 1.6%</font> pre-market to $27.57.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526161\" data-linked=\"STM raised ahead of growth drivers\" data-tweet=\"$STM - STM raised ahead of growth drivers https://seekingalpha.com/news/3526161-stm-raised-ahead-of-growth-drivers?source=tweet\" data-url=\"https://seekingalpha.com/news/3526161-stm-raised-ahead-of-growth-drivers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526155\" data-ts=\"1576244428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526155-credit-suisse-cuts-view-on-gilead-in-premarket-analyst-action\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse cuts view on Gilead in premarket analyst action</a></h4><ul><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) initiated with Market Perform rating at Oppenheimer.</li><li>Exact Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/EXAS' title='Exact Sciences Corporation'>EXAS</a>) initiated with Buy rating and $120 (40% upside) price target at Dougherty &amp; Company.</li><li>Ionis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/IONS' title='Ionis Pharmaceuticals, Inc.'>IONS</a>) initiated with Outperform rating and $77 (24% upside) price target at Oppenheimer.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) upgraded to Neutral with a $300 (2% upside) price target at Credit Suisse. Shares up <font color=\"green\">1%</font> premarket.</li><li>Bluebird bio (NASDAQ:<a href='https://seekingalpha.com/symbol/BLUE' title='bluebird bio, Inc.'>BLUE</a>) upgraded to Outperform with a $135 (61% upside) price target at Oppenheimer. Shares up <font color=\"green\">3% </font>premarket.</li><li>Bristol-Myers Squibb (NYSE:<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a>) upgraded to Buy with an $80 (25% upside) price target at Argus Research.</li><li>NuVasive (NASDAQ:<a href='https://seekingalpha.com/symbol/NUVA' title='NuVasive, Inc.'>NUVA</a>) upgraded to Outperform at SVB Leerink.</li><li>Regeneron Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a>) upgraded to Outperform with a $400 (8% upside) price target at Credit Suisse. Shares up <font color=\"green\">1%</font> premarket.</li><li>Aimmune Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics, Inc.'>AIMT</a>) downgraded to Neutral with a $30 (5% downside risk) price target at Credit Suisse. Shares down <font color=\"red\">2%</font> premarket.</li><li>Galapagos NV (NASDAQ:<a href='https://seekingalpha.com/symbol/GLPG' title='Galapagos NV'>GLPG</a>) downgraded to Neutral with a \u20ac169 (11% downside risk) price target at Credit Suisse. Shares down <font color=\"red\">2%</font> premarket in U.S.</li><li>Gilead Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a>) downgraded to Underperform with a $63 (7% downside risk) price target at Credit Suisse. Shares down <font color=\"red\">1%</font> premarket.</li><li>Neurocrine Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/NBIX' title='Neurocrine Biosciences, Inc.'>NBIX</a>) downgraded to Neutral with a $110 (1% downside risk) price target at Credit Suisse. Shares down <font color=\"red\">1%</font> premarket.</li><li>NextGen Healthcare (NASDAQ:<a href='https://seekingalpha.com/symbol/NXGN' title='NextGen Healthcare, Inc.'>NXGN</a>) downgraded to Neutral with a $17 (1% upside) price target at Cantor Fitzgerald.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526155\" data-linked=\"Credit Suisse cuts view on Gilead in premarket analyst action\" data-tweet=\"$ARWR $EXAS $IONS - Credit Suisse cuts view on Gilead in premarket analyst action https://seekingalpha.com/news/3526155-credit-suisse-cuts-view-on-gilead-in-premarket-analyst-action?source=tweet\" data-url=\"https://seekingalpha.com/news/3526155-credit-suisse-cuts-view-on-gilead-in-premarket-analyst-action\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526153\" data-ts=\"1576244042\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HBI\" target=\"_blank\">HBI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526153-hanesbrandsminus-2-after-rare-bear-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hanesbrands -2% after rare bear call</a></h4><ul> <li>Shares of Hanesbrands (NYSE:<a href='https://seekingalpha.com/symbol/HBI' title='Hanesbrands Inc.'>HBI</a>) are on watch after Bank of America Merrill Lynch moves to an Underperform rating after having HBI slotted at Neutral.</li> <li>Analyst Heather Balsky warns on the risk of multiple contraction on Champion sales and the negative impact from the C9 exit at Target.</li> <li>The firm lowers its price target to $13 from $16. The average sell-side PT on Hanesbrands is $18.36.</li> <li>BAML is the only bear on Wall Street, with 5 Buy-equivalent ratings and 9 Neutral-equivalent ratings standing on the <a href=\"https://seekingalpha.com/symbol/HBI/ratings/sell-side-ratings\" target=\"_blank\">books</a>.</li> <li>Shares of Hanesbrands are <font color=\"red\">down 2.17%</font> in premarket trading.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526153\" data-linked=\"Hanesbrands -2% after rare bear call\" data-tweet=\"$HBI - Hanesbrands -2% after rare bear call https://seekingalpha.com/news/3526153-hanesbrandsminus-2-after-rare-bear-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3526153-hanesbrandsminus-2-after-rare-bear-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526147\" data-ts=\"1576243156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COP\" target=\"_blank\">COP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526147-conocophillips-adds-new-bull\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ConocoPhillips adds a new bull</a></h4><ul> <li>Atlantic Equities starts off coverage on ConocoPhillips (NYSE:<a href='https://seekingalpha.com/symbol/COP' title='ConocoPhillips Company'>COP</a>) with an Overweight rating.</li> <li>The research firm assigns a price target of $75 to rep 20% upside potential. The average sell-side PT on ConocoPhillips is $72.71.</li> <li>Shares of ConocoPhillips are <font color=\"green\">up 0.66%</font> premarket to $63.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526147\" data-linked=\"ConocoPhillips adds a new bull\" data-tweet=\"$COP - ConocoPhillips adds a new bull https://seekingalpha.com/news/3526147-conocophillips-adds-new-bull?source=tweet\" data-url=\"https://seekingalpha.com/news/3526147-conocophillips-adds-new-bull\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526141\" data-ts=\"1576242495\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526141-biolinerx-up-21-premarket-on-positive-blminus-8040-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx up 21% premarket on positive BL-8040 data</a></h4><ul><li>BioLineRx (NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) is up <font color=\"green\">21%</font> premarket on the heels of updated data from the <a href=\"https://seekingalpha.com/pr/17727672-biolinerx-announces-updated-phase-2a-data-from-triple-combination-arm-of-combat-keynoteminus\" target=\"_blank\">triple combination arm</a> of the ongoing <a href=\"https://clinicaltrials.gov/ct2/show/NCT02826486?lead=BioLineRx&amp;phase=1&amp;draw=2&amp;rank=1\" target=\"_blank\">Phase 2a COMBAT/KEYNOTE-202</a> study.</li><li>The triple combination arm focuses on second-line pancreatic cancer patients and is expected to include approx. 40 patients originally diagnosed with unresectable metastatic pancreatic adenocarcinoma who have progressed following first-line gemcitabine-based therapy. As of today's date, 36 out of 40 patients have been enrolled.</li><li>An overall response rate &#40;ORR&#41; of 32% and a disease control rate &#40;DCR&#41; of 77% was observed compared to the current chemotherapy standard-of-care treatment in second-line patients with ORR of 17% and DCR of 52%.</li><li>Out of the 7 partial responders, 4 responders showed a reduction in tumor burden of &gt;50%.</li><li>Median duration of clinical benefit until progression for the 17 patients with disease control is 7.8 months.</li><li>Progression-free and overall survival data remain on track for mid-2020.</li><li>The combination was generally well tolerated.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3523985-biolinerx-reports-interim-data-on-blminus-8040-combo-in-pancreatic-cancer\" target=\"_blank\">BioLineRx reports interim data on BL-8040 combo in pancreatic cancer</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3526141\" data-linked=\"BioLineRx up 21% premarket on positive BL-8040 data\" data-tweet=\"$BLRX - BioLineRx up 21% premarket on positive BL-8040 data https://seekingalpha.com/news/3526141-biolinerx-up-21-premarket-on-positive-blminus-8040-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3526141-biolinerx-up-21-premarket-on-positive-blminus-8040-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526140\" data-ts=\"1576242326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYNA\" target=\"_blank\">SYNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526140-synaptics-raised-on-suspected-apple-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synaptics raised on suspected Apple win</a></h4><ul><li>Susquehanna says yesterday's Broadcom (NASDAQ:<a href='https://seekingalpha.com/symbol/AVGO' title='Broadcom Inc.'>AVGO</a>) earnings report might show that Synaptics (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNA' title='Synaptics Incorporated'>SYNA</a>) won a contract from Apple.</li><li>The firm notes that Broadcom said it lost a mixed signal custom product from its largest customer. Analyst Christopher Rolland notes that Apple is reportedly looking to move to flexible OLED displays for iPhones.</li><li>Synaptics recently disclosed a Huawei win, which Susquehanna thinks was related to flexible OLED tech.</li><li>Susquehanna maintains a Neutral rating on SYNA and raises the target from $46 to $60. The company has a Neutral average <a href=\"https://seekingalpha.com/symbol/SYNA/ratings/sell-side-ratings?s=syna\" target=\"_blank\">Sell Side rating</a>.</li><li>SYNA shares are <font color=\"green\">up 1.6%</font> pre-market to $60.26.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526140\" data-linked=\"Synaptics raised on suspected Apple win\" data-tweet=\"$SYNA $AVGO $SYNA - Synaptics raised on suspected Apple win https://seekingalpha.com/news/3526140-synaptics-raised-on-suspected-apple-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3526140-synaptics-raised-on-suspected-apple-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526130\" data-ts=\"1576241643\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526130-wdc-mu-gain-rbc-calls-memory-bottom\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WDC, MU gain as RBC calls memory bottom</a></h4><ul><li>RBC met with Western Digital (NASDAQ:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>) management and is now \"officially calling the bottom on memory pricing.\"</li><li>Analyst Mitch Steves: \"We are buyers of memory at this point and believe we\u2019ll be past inventory issues by the end of the year.\"</li><li>Steves expects price increases for both NAND and DRAM.</li><li>The analyst notes that Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a>) has \"sounded negative due to aggressive inventory de-stocking.\"</li><li>RBC maintains an Outperform rating and $64 target on WDC. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/WDC/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>Western Digital shares are <font color=\"green\">up 1.4%</font> pre-market to $54.46. Micron shares are <font color=\"green\">up 1.6%</font> to $51.77.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526130\" data-linked=\"WDC, MU gain as RBC calls memory bottom\" data-tweet=\"$WDC $MU - WDC, MU gain as RBC calls memory bottom https://seekingalpha.com/news/3526130-wdc-mu-gain-rbc-calls-memory-bottom?source=tweet\" data-url=\"https://seekingalpha.com/news/3526130-wdc-mu-gain-rbc-calls-memory-bottom\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526124\" data-ts=\"1576240400\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526124-jmp-turns-bullish-on-snap-monetization\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JMP turns bullish on Snap monetization</a></h4><ul><li>JMP Securities upgrades Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) from Market Perform to Market Outperform with a $20 target.</li><li>Analyst Ronald Josey cites higher confidence in Snap's ability to grow its user base and monetization thanks to new ad products and a sales team reorganization.</li><li>Josey notes that Snap's valuation is \"among the most expensive in our coverage universe.\"</li><li>Snap shares are <font color=\"green\">up 1.9%</font> pre-market to $14.72.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526124\" data-linked=\"JMP turns bullish on Snap monetization\" data-tweet=\"$SNAP - JMP turns bullish on Snap monetization https://seekingalpha.com/news/3526124-jmp-turns-bullish-on-snap-monetization?source=tweet\" data-url=\"https://seekingalpha.com/news/3526124-jmp-turns-bullish-on-snap-monetization\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526116\" data-ts=\"1576239849\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XPER\" target=\"_blank\">XPER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526116-xperiplus-2_3-after-raising-billings-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xperi +2.3% after raising billings outlook</a></h4><ul><li>Xperi (NASDAQ:<a href='https://seekingalpha.com/symbol/XPER' title='Xperi Corporation'>XPER</a>) <a href=\"https://seekingalpha.com/pr/17727644-xperi-increases-fourth-quarter-and-full-year-2019-billings-outlook\" target=\"_blank\">raises</a> its Q4 billings outlook from $111-115M to $124-126M.</li><li>For FY19, the billings view increases from $398-402M to $411-413M.</li><li>Xperi says the increase is primarily due to a one-time payment connected to an IP licensing resolution.</li><li>XPER shares are <font color=\"green\">up 2.3%</font> pre-market to $20.35.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526116\" data-linked=\"Xperi +2.3% after raising billings outlook\" data-tweet=\"$XPER - Xperi +2.3% after raising billings outlook https://seekingalpha.com/news/3526116-xperiplus-2_3-after-raising-billings-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3526116-xperiplus-2_3-after-raising-billings-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526113\" data-ts=\"1576239261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEMD\" target=\"_blank\">AEMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526113-aethlon-medical-down-42-premarket-on-pricing-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aethlon Medical down 42% premarket on pricing public offering</a></h4><ul> <li>Aethlon Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/AEMD' title='Aethlon Medical, Inc.'>AEMD</a>) has <a href=\"https://seekingalpha.com/pr/17727650-aethlon-medical-announces-pricing-of-5-million-public-offering\" target=\"_blank\">priced</a> its public offering of 3,333,334 shares of common stock (which includes pre-funded warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 3,333,334 common shares at $1.50 per share, for expectd gross proceeds of ~$5M.</li><li>Underwriters' over-allotment is an additional 499,999 common stock and/or warrants.</li><li>The common warrants have an exercise price of $1.50 per share, and will expire five years from the date of issuance.</li>  <li>Net proceeds will be used for the clinical trials, working capital and other general corporate purposes.</li><li>Closing date is December 17.</li><li>Shares are down <font color=\"red\">42%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526113\" data-linked=\"Aethlon Medical down 42% premarket on pricing public offering\" data-tweet=\"$AEMD - Aethlon Medical down 42% premarket on pricing public offering https://seekingalpha.com/news/3526113-aethlon-medical-down-42-premarket-on-pricing-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526113-aethlon-medical-down-42-premarket-on-pricing-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526110\" data-ts=\"1576238799\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HZNP\" target=\"_blank\">HZNP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526110-horizon-shares-halted-for-ad-com-review-of-teprotumumab\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Horizon shares halted for Ad Com review of teprotumumab</a></h4><ul><li>Nasdaq has suspended trading in Horizon Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/HZNP' title='Horizon Therapeutics Public Limited Company'>HZNP</a>) for today's FDA advisory committee <a href=\"https://seekingalpha.com/news/3525641-ad-com-friday-for-horizons-teprotumumab-for-thyroid-eye-disease\" target=\"_blank\">meeting </a>on teprotumumab for the treatment of thyroid eye disease.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526110\" data-linked=\"Horizon shares halted for Ad Com review of teprotumumab\" data-tweet=\"$HZNP - Horizon shares halted for Ad Com review of teprotumumab https://seekingalpha.com/news/3526110-horizon-shares-halted-for-ad-com-review-of-teprotumumab?source=tweet\" data-url=\"https://seekingalpha.com/news/3526110-horizon-shares-halted-for-ad-com-review-of-teprotumumab\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526109\" data-ts=\"1576238651\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ETSY\" target=\"_blank\">ETSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526109-etsyplus-1-after-new-bull-jumps-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Etsy +1% after new bull jumps in</a></h4><ul> <li>SunTrust Robinson Humphrey initiates coverage on Etsy (NASDAQ:<a href='https://seekingalpha.com/symbol/ETSY' title='Etsy, Inc.'>ETSY</a>) with a Buy rating.</li> <li>The research firm sets a price target of $55 on the online retailer to rep +30% upside potential. The <a href=\"https://seekingalpha.com/symbol/ETSY/ratings/sell-side-ratings\" target=\"_blank\">average sell-side PT</a> on Etsy is way up at $66.08.</li> <li>Shares of Etsy are <font color=\"green\">up 1.24%</font> premarket to $42.50 vs. the 52-week trading range of $39.76 to $73.35.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526109\" data-linked=\"Etsy +1% after new bull jumps in\" data-tweet=\"$ETSY - Etsy +1% after new bull jumps in https://seekingalpha.com/news/3526109-etsyplus-1-after-new-bull-jumps-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3526109-etsyplus-1-after-new-bull-jumps-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526107\" data-ts=\"1576238507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526107-sarepta-up-36-premarket-on-fda-nod-for-golodirsen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta up 36% premarket on FDA nod for golodirsen</a></h4><ul><li>Sarepta Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRPT' title='Sarepta Therapeutics, Inc.'>SRPT</a>) is set to add about $2.7B to its market cap today on the heels of the FDA's <a href=\"https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation\" target=\"_blank\">accelerated approval</a> of Vyondys 53 (golodirsen) for certain Duchenne muscular dystrophy &#40;DMD&#41; patients <a href=\"https://seekingalpha.com/news/3526041-sarepta-therapeutics-spikes-after-accelerated-fda-approval-of-dmd-treatment\" target=\"_blank\">announced</a> yesterday after the close.</li><li>Golodirsen is designed to bind to exon 53 of dystrophin pre-mRNA which results in \"skipping\" the exon. EXONDYS 51 (eteplirsen), by comparison, is designed to skip exon 51. About 8% of DMD patients are amenable to exon 53 skipping.</li><li>Shares up <font color=\"green\">36%</font> premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526107\" data-linked=\"Sarepta up 36% premarket on FDA nod for golodirsen\" data-tweet=\"$SRPT - Sarepta up 36% premarket on FDA nod for golodirsen https://seekingalpha.com/news/3526107-sarepta-up-36-premarket-on-fda-nod-for-golodirsen?source=tweet\" data-url=\"https://seekingalpha.com/news/3526107-sarepta-up-36-premarket-on-fda-nod-for-golodirsen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526097\" data-ts=\"1576235346\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPU\" target=\"_blank\">ASPU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526097-aspen-group-readies-equity-offering-shares-down-7-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aspen Group readies equity offering; shares down 7% after-hours</a></h4><ul> <li>Aspen Group (NASDAQ:<a href='https://seekingalpha.com/symbol/ASPU' title='Aspen Group, Inc.'>ASPU</a>) launches a <a href=\"https://seekingalpha.com/pr/17727290-aspen-group-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">public offering</a> of common stock.</li><li>Price, volume and terms have yet to be announced.</li>  <li>ASPU  <font color=\"red\">-7%</font> pre-market to  $7.05</li><li>Source: <a href=\"https://seekingalpha.com/pr/17727290-aspen-group-announces-proposed-public-offering-of-common-stock\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526097\" data-linked=\"Aspen Group readies equity offering; shares down 7% after-hours\" data-tweet=\"$ASPU - Aspen Group readies equity offering; shares down 7% after-hours https://seekingalpha.com/news/3526097-aspen-group-readies-equity-offering-shares-down-7-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3526097-aspen-group-readies-equity-offering-shares-down-7-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526089\" data-ts=\"1576233383\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PHR\" target=\"_blank\">PHR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526089-phreesia-prices-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phreesia prices secondary offering</a></h4><ul> <li>Phreesia (NYSE:<a href='https://seekingalpha.com/symbol/PHR' title='Phreesia, Inc.'>PHR</a>) has <a href=\"https://seekingalpha.com/pr/17727549-phreesia-announces-pricing-of-secondary-offering\" target=\"_blank\">priced</a> its underwritten secondary offering of 6.75M common shares at $26/share.</li><li>The Selling Stockholders have granted the underwriters an option to purchase up to 1,012,500 additional shares.</li> <li>Closing date is December 17.</li><li>Phreesia will not receive any proceeds from the Secondary Offering.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3526089\" data-linked=\"Phreesia prices secondary offering\" data-tweet=\"$PHR - Phreesia prices secondary offering https://seekingalpha.com/news/3526089-phreesia-prices-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3526089-phreesia-prices-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526086\" data-ts=\"1576233169\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526086-futures-point-to-fresh-record-highs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Futures point to fresh record highs</a></h4><ul><li>Stocks soared across the board overnight on news of an imminent trade deal between the U.S. and China, as well as the end to Brexit deadlock, as traders crave some certainty in what is already a banner year for markets.</li><li>Shanghai <font color=\"green\">advanced 1.8%</font> and the Euro Stoxx 50 posted <font color=\"green\">gains of 1.5%</font>, while U.S. equity index futures are <font color=\"green\">ahead by 0.5%</font>, setting up fresh record highs for Wall Street.</li><li>A gauge of U.S. consumer health is also on tap as the Commerce Department releases retail sales for November, which includes the busy Black Friday holiday.</li></ul><div class=\"tiny-share-widget\" data-id=\"3526086\" data-linked=\"Futures point to fresh record highs\" data-tweet=\"Futures point to fresh record highs https://seekingalpha.com/news/3526086-futures-point-to-fresh-record-highs?source=tweet\" data-url=\"https://seekingalpha.com/news/3526086-futures-point-to-fresh-record-highs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>48&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3526050\" data-ts=\"1576219735\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EWU\" target=\"_blank\">EWU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3526050-sterling-surges-boris-wins-big\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sterling surges as Boris wins big</a></h4><ul><li>Boris Johnson's Conservative Party has <a href=\"https://news.sky.com/story/general-election-conservatives-win-with-commanding-majority-sky-news-forecast-11885143\" target=\"_blank\">secured</a> a majority in the House of Commons after winning their 326th seat, and is likely to win 363 seats in Parliament, a gain of 45 seats from the 2017 election.</li><li>That would be the best results since it won 376 seats under Margaret Thatcher in 1987, giving Johnson a comfortable parliamentary majority to win backing for his Brexit deal and leave the EU by the end of next month.</li><li>While that reduces a significant amount of Brexit uncertainty, the U.K. could still have a hard exit from the single market and customs union at the end of 2020 if the two sides don't manage to strike a trade agreement.</li><li>What about U.S. trade? \"Britain and the United States will now be free  to strike a massive new Trade Deal after BREXIT,\" President Trump <a href=\"https://twitter.com/realDonaldTrump/status/1205368801438707713\" target=\"_blank\">wrote</a> on Twitter. \"This deal has the potential to be far bigger and more lucrative than any deal that could be made with the EU.\"</li><li>Sterling is trading at $1.3474, more than <font color=\"green\">2.4% higher</font>, while FTSE 100 futures are <font color=\"green\">up 0.2%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWU' title='iShares MSCI United Kingdom ETF'>EWU</a>, <a href='https://seekingalpha.com/symbol/FXB' title='Invesco CurrencyShares British Pound Sterling Trust ETF'>FXB</a>, <a href='https://seekingalpha.com/symbol/IRL' title='New Ireland Fund'>IRL</a>, <a href='https://seekingalpha.com/symbol/EIRL' title='iShares MSCI Ireland Capped ETF'>EIRL</a>, <a href='https://seekingalpha.com/symbol/GBB' title='iPath GBP/USD Exchange Rate ETN'>OTC:GBB</a>, <a href='https://seekingalpha.com/symbol/EWUS' title='iShares Trust - iShares MSCI United Kingdom Small-Cap ETF'>EWUS</a>, <a href='https://seekingalpha.com/symbol/FKU' title='First Trust United Kingdom AlphaDex ETF'>FKU</a>, <a href='https://seekingalpha.com/symbol/DGBP' title='VelocityShares Daily 4X Long USD vs. GBP ETN'>DGBP</a>, <a href='https://seekingalpha.com/symbol/HEWU' title='iShares Currency Hedged MSCI United Kingdom ETF'>HEWU</a>, <a href='https://seekingalpha.com/symbol/FLGB' title='Franklin Templeton ETF Trust - Franklin FTSE United Kingdom ETF'>FLGB</a>, <a href='https://seekingalpha.com/symbol/UGBP' title='VelocityShares Daily 4X Long GBP vs. USD ETN'>UGBP</a>, <a href='https://seekingalpha.com/symbol/ZGBR' title='SPDR Index Shares Funds - SPDR Solactive United Kingdom ETF'>ZGBR</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3526050\" data-linked=\"Sterling surges as Boris wins big\" data-tweet=\"$EWU $FXB $IRL - Sterling surges as Boris wins big https://seekingalpha.com/news/3526050-sterling-surges-boris-wins-big?source=tweet\" data-url=\"https://seekingalpha.com/news/3526050-sterling-surges-boris-wins-big\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>101&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}